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Abstract
We propose a Bayesian approach for estimating branching tree mixture models to compare drug-resistance pathways (i.e.
patterns of sequential acquisition of resistance to individual antibiotics) that are observed among Mycobacterium
tuberculosis isolates collected from treatment-naı ¨ve and treatment-experienced patients. Resistant pathogens collected
from treatment-naı ¨ve patients are strains for which fitness costs of resistance were not sufficient to prevent transmission,
whereas those collected from treatment-experienced patients reflect both transmitted and acquired resistance, the latter of
which may or may not be associated with lower transmissibility. The comparison of the resistance pathways constructed
from these two groups of drug-resistant strains provides insight into which pathways preferentially lead to the
development of multiple drug resistant strains that are transmissible. We apply the proposed statistical methods to data
from worldwide surveillance of drug-resistant tuberculosis collected by the World Health Organization over 13 years.
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Introduction
Tuberculosis (TB) is an infectious disease caused by Mycobac-
terium tuberculosis and is transmitted between hosts through the
respiratory route. The appearance of TB resistant to multiple
antibiotics threatens global control strategies that depend on the
efficacy of standard combinations of these drugs. Drug-resistant
TB in communities initially arises as a result of the sporadic
appearance and subsequent selection of drug-resistant M. tubercu-
losis mutants in individuals receiving inadequate treatment.
Individuals acquiring drug-resistance as a result of poor TB
treatment may then transmit resistant organisms to their
respiratory contacts.
Figure 1 displays mechanisms leading to drug resistant TB
infection in treatment-naı ¨ve and treatment-experienced patients.
Drug-resistance in treatment-naı ¨ve TB patients reflects primary
transmission of resistant strains; in contrast, drug-resistance in TB
patients who have previously been treated with anti-TB antibiotics
may reflect either transmitted resistance or resistance acquired
during previous treatment. Resistant strains observed among
treatment-naı ¨ve TB patients have demonstrated sufficiently high
reproductive fitness to have been transmitted and caused disease.
By contrast, resistant strains that are observed among treatment-
experienced patients arise from either transmission from another
host or from within-host selection of sporadically occurring
mutants under drug pressure. Drug resistant strains arising as a
result of this second mechanism may not be as easily transmitted to
secondary hosts as drug strains that have already demonstrated
their ability to infect and cause disease in secondary hosts.
Determining which strains are sufficiently fit to be transmitted and
cause disease can aid in developing effective strategies to combat
the spread of resistance.
Probabilistic graphical models, e.g. branching tree mixture
models, have been used to infer the sequence of several binary
events that have occurred in an unknown order [1–3]. These
models can potentially provide public health benefit as they only
require cross-sectional data, often easily and abundantly available,
and are applicable to any biological system that follows an
ascending Markov process. Past use of these models include
describing the order of acquiring copy number aberrations in renal
cancer, modeling the development of HIV genetic mutations
associated with antiretroviral resistance and characterizing the
acquisition of anti-TB drug resistance from phenotypic TB data
[1–3]. Knowledge regarding these longitudinal processes may be
useful in directing research for disease control.
Considerable work has been done in defining and fitting
branching tree models. The single mutagenetic tree introduced by
Desper et al. [1], describes the progression of a set of events, or
pathway, for a population. The model assumes that there are no
reversions following an event and that for each event, there is a
PLOS Computational Biology | www.ploscompbiol.org 1 March 2013 | Volume 9 | Issue 3 | e1002973unique pathway leading to it. To broaden this class of models for
settings where the latter assumption does not hold, Beerenwinkel
et al. [2] introduced mixture models that allow for the existence of
multiple evolutionary pathways leading to the same event. Izu et
al. [3] developed a Bayesian approach to identifying a mixture
model and estimating the associated parameters.
Branching trees are useful in the context of TB because the
probability of reverse mutations is very small (validating the
ascending markov assumption), and global cross-sectional pheno-
typic drug resistance data are publicly available [4]. In analyses of
genetic data, an event is a specific mutation; whereas in analyses of
phenotypic data, sets of genetic mutations are grouped into single
events. For example, the event ‘‘resistance to isoniazid’’ would
comprise all patterns of genetic mutations which confer isoniazid
resistance. Although phenotypic data does not allow examination
of the ordering in which such mutations emerge, such data are
more readily available and can provide a basis for generating
hypotheses that can subsequently be tested with genetic data.
Below, we expand the use of these models beyond their previous
application for describing the progression of events in a single
population. This paper develops a Bayesian approach to compare
pathways in two different populations using branching trees in
which some tree parameters are prespecified. We apply these
methods to investigate the relationship between drug resistance in
treatment-naı ¨ve and in treatment-experienced patients. By com-
paring branching trees from these two groups of patients, we gain
Figure 1. Mechanisms of TB drug resistance in treatment-naı ¨ve and experienced patients. The first pathway describes patients who test
positive for resistance to anti-TB drugs prior to their first treatment episode. These treatment- naı ¨ve patients were initially infected with a drug-
resistant strain. The second pathway describes patients who were infected by a drug resistant strain and failed their first course of treatment. After
their first course of treatment, they tested positive for resistance to anti-TB drugs. The final pathway describes patients who were infected by a drug
susceptible strain and failed their first treatment episode because they acquired resistance via spontaneous mutation.
doi:10.1371/journal.pcbi.1002973.g001
Author Summary
Drug-resistant tuberculosis (TB) initially arises as a result of
the sporadic appearance and subsequent selection of
drug-resistant M. tuberculosis mutants. Such strains may or
may not be associated with fitness costs affecting their
ability to transmit and cause disease. Resistant pathogens
collected from treatment-naı ¨ve patients are strains for
which fitness costs of resistance were not sufficient to
prevent transmission. Those collected from treatment-
experienced patients reflect strains that may or may not be
associated with lower transmissibility. Determining which
strains are sufficiently fit to be transmitted and cause
disease can aid in developing effective strategies to
combat the spread of resistance. Branching trees are
graphical models used to infer the sequence of several
binary events (i.e. a pathway) that have occurred in an
unknown order. We propose a novel method using
branching trees with prespecified components to compare
evolutionary pathways among different populations. We
apply our model to understand if there are unique drug-
resistant pathways found only amongst treatment expe-
rienced patients that might reflect acquired resistant
disease associated with fitness costs that limits its ability
to transmit. Our methods can be generalized to any
biological process for which the assumption of an
ascending markov process applies.
Mixture Models with Prespecified Elements
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capable of being transmitted and causing secondary disease.
Methods
Branching trees
We follow Desper et al. in our notation for branching tree
models. A branching tree, denoted by T ~(V,r,E,bp), is a special
Bayesian network that consists of a set of nodes or vertices, a root,
a set of edges connecting the vertices, and edge weights. Vertices
represent the event of a binary random variable and the root
represents the binary random variable indicating whether none or
at least one of the events characterized by the vertices have
occurred. The edges connecting the nodes have weights equal to
the conditional probability of the child event given the prior
occurrence of the parent event. As the branching trees described
here do not take time into account, the edge weights are not
informative about the times to occurrences of events. An example
is provided by the two trees in Figure 2 with edge weights
bp1,1~0:1 and bp2,1~0:9. From these, we infer that prevalence of
drug1 is higher but not that resistance to it occurs faster in the
latter compared with the former tree. For more details on timed
branching tree used in oncogenesis see Desper et al.
Branching trees model the joint distributions of events and
impose constraints on the dependencies among events and on the
order in which they can occur. Let V~fr,z1,z2,:::,zng be the set of
nodes for which r is the root; (zu,zv)[E denote the edge directed
from node zu pointing towards node zv ;and bp be the probability
mapping such that bp : E?½0,1 . A path from z1 to zm is a
sequence of edges (z1,z2)(z2,z3):::(zm{1,zm) and z1 is an ancestor
of zm. The path is a cycle if z1~zm. A branching tree imposes the
restriction that there be no cycles and that each edge must be
directed toward a different node. A node with no offspring is called
a leaf. One particular branching tree to define is a star tree.
In this paper, the nodes represent the acquisition of drug
resistance to one or more drugs and the root represents a wild type
state (i.e. full sensitivity to all anti-TB drugs). The edges connecting
the nodes signify that the event represented by the offspring (child)
node can only occur given the prior occurrence of the event
represented by the parent node. The edge weights are the
conditional probabilities of these events.
Mixture models
Because a branching tree requires that each edge be directed
toward a different node, single branching trees may not be
sufficient to describe the underlying processes of interest.
Beerenwinkel et al. [2] introduced mixture models in order to
accommodate the existence of multiple evolutionary pathways
leading to the same node. A K-tree mixture model is comprised of
K branching trees, T 1,:::,T K, and their respective tree weights,
a1,:::,aK, where ak is the marginal probability that a random
individual follows a pathway represented by the kth tree. Let cik
denote the probability that the ith individual follows a pathway
represented by T k (Beerenwinkel et al. [2] referred to this
probability as the responsibility of T k). We refer to a tree structure as
the graph of the mixture model without the edge weights, i.e. the
collection of trees, T ’ k~(V,E,r).
Mixture models often contain a special noise component or star
tree, in which all nodes originate in the root. Figure 2 provides an
example of a mixture model, in which the first tree is the star tree.
Mixture models which include a star tree ensure that every
possible multinomial state has probability greater than zero.
Estimating mixture models that are partially specified
We adapt the two-step process introduced in Izu et al. to
estimate mixture models, in which aspects are prespecified
Figure 2. An example of the graphical display of a 2-tree mixture model with three nodes. bp is the set of edge weights defined as the
conditional probability of the child node given the prior occurrence of the parent event. a1 and a2 are the probability that an individual follows a
pathway represented by the first and second tree, respectively.
doi:10.1371/journal.pcbi.1002973.g002
Mixture Models with Prespecified Elements
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X K
k~1
akT k
where k~(1,:::,Kp,Kpz1,:::,K) and T k is treated as known for
Kp of the K trees. The first step estimates the structures of the
remaining trees. To accomplish this, we adjust the EM-like
algorithm in Beerenwinkel et al. [2] to account for the prespecified
portion of the model. This involves iterating between estimating
the K responsibilities for each individual and reconstructing the
remaining K{Kp trees using the data weighted by the respon-
sibilities. Given an estimate of M~
PK
k~1 akT k the responsibility
of the kth tree for the ith sample is estimated (E step) by
cik~
akL(xiDT k)
XK
l~1 alL(xiDT l)
:
Following this step, T k for k~fKpz1,:::,Kg is reconstructed by
using the maximum branching algorithm (M step) found in Desper
et al. with the following adjusted joint and marginal probabilities
^ p pk,u~
1
Nk
X N
i~1
cikI(Xi,u~1)
^ p pk,uv~
1
Nk
X N
i~1
cikI(Xi,u~1)I(Xi,v~1)
Nk~
X N
i~1
cik:
As discussed in Izu et al. we can also compose a set of candidate
models that include similar, but different, structures for the
unspecified trees and then use a given criteria to choose the best
model. In certain settings, it may be reasonable to assume the
structure of all trees in the model thereby avoiding the need for the
first step.
Given the structure of the K trees, the second step uses Bayesian
methods to estimate the parameters associated with the partially-
known mixture model. Let y represent a multinomial random
variable whose outcomes are determined by the pattern of events
for the set of binary random variables or vertices. There are 2n
possible outcomes, where n is the number of vertices. Let
p1,k,:::,p2n,k be the corresponding probabilities of each outcome
associated with the kth tree. For example, for the mixture model
shown in Figure 2 there are 23~8 possible outcomes for the
multinomial distribution. If p4 corresponds to the event resistance
to drug3 but not drug1 or drug2, the probability of this outcome is
p4~a1(1{bp1,1)(1{bp1,2)bp1,3za2   0:
Let y*Multinomial(a1p1,:::,aKpK). We place non-informative
priors on the tree weights, ak, and the parameters associated with
T k. The posterior distribution of these parameters can be obtained
from an MCMC implementation in WinBUGS.
Measure of similarity
To use mixture models to compare two populations, A and B,
we include trees derived from data on population A as prespecified
elements in our mixture model for population B. Tree weights
associated with these trees provide a measure of the similarity
between the two populations, which we define below. The mixture
model for population B is
M~
X K
k~1
akT k
where KP of the K trees describe pathways that are also seen in
population A, and the remaining trees describe pathways seen only
in population B. We define the measure of similarity as
PKP
k~1 ak.
From our definition of ak above, the measure of similarity is the
probability that an individual from population B follows any of the
pathways resulting from the model describing population A. Using
the bayesian methods described above, we can obtain a posterior
distribution for this quantity.
Application to drug resistant TB in treatment-naı ¨ve and
treatment-experienced patients
The data we analyze are obtained from Anti-Tuberculosis Drug
Resistance in the World, Fourth Global Report [4]. These data
arise from surveillance in countries where all notified culture-
positive TB cases received drug susceptibility testing (DST) and
from population-representative surveys in countries where not all
TB cases routinely receive DST. Between 1994 and 2007, DST
results were collected from patients from 138 settings in 114
countries and 2 Special Administrative Regions (SARs) of China.
The anti-TB drugs reported include isoniazid (H), rifampin (R),
ethambutol (E) and streptomycin (S). Twenty-nine settings were
excluded because data were either only reported for treatment-
naı ¨ve patients or combined for naı ¨ve and treatment-experienced
patients, leaving a total of 85,672 samples from treatment-naı ¨ve
patients and 18,619 samples from treatment-experienced patients.
Seven different regions were considered (AFR=African region,
AMR=region of the Americas, EMR=Eastern Mediterranean
region, FSU=Former Soviet Union region, NFSU-EUR=Non-
Former Soviet Union European region, SEAR=South-East Asian
region, WPR=Western Pacific region) as shown in Table 1.
Originally, all European countries were included in a single
region. However, the prevalence of resistance to any anti-TB drug
is significantly higher in countries of the former Soviet Union than
in other European countries: 39% (95% CI: 38–40) and
8.2%(95% CI: 7.8, 8.5), respectively, among treatment-naı ¨ve
cases and 71% (95% CI: 70–72) versus 20% (95% CI: 18, 22)
among treatment experienced cases. Because of this large
difference, we split the European region into two sub-regions.
Resistance pathways may vary between regions, both because of
geographic heterogeneity in strain lineage and because of
differential selective pressure due to different historic usage of
anti-tuberculosis drugs [5]. As a consequence, we analyze data
from each region separately. Methods described in Izu et al. are
used to analyze the data from the treatment-naı ¨ve patients. The
resulting tree structures and their corresponding edge weights
comprise the prespecified components in the mixture model fit to
data from treatment-experienced patients.
Results
Results for treatment-naı ¨ve patients
In the resulting mixture models for treatment-naı ¨ve patients,
models from all seven regions contain two trees. The non-star tree
for the models describing the AMR, EMR, FSU, SEAR and WPR
is shown in Figure 3(a)-these are all trees with a single leaf. Izu et
Mixture Models with Prespecified Elements
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well when the underlying data generating tree structure has a
single leaf. The non-star tree from the models describing AFR and
NFSU-EUR is shown in Figure 3(b). For each region, estimates for
the tree and edge weight parameters are shown in Table 2. ai is an
estimate of the proportion of the population following the ith tree.
The four columns following ai represent the edges and
corresponding edge weights associated with tree i. The edge
weight is the conditional probability of resistance to the drug
indicated by the child node given resistance to the drug indicated
by the parent node. If the parent node is the root (WT), the edge
weight is the marginal probability of resistance to the drug
indicated by the child node. For example, in the AFR, 16% of all
TB strains follow pathways described by the first tree which has
the set of edges E={WT?H, WT?R, WT?E, WT?S}. 84%
of TB strains follow pathways to resistance described by the second
tree with the set of edges E={WT?H, H?R, H?E, R?S}. In
the latter, the conditional probability of resistance to rifampin
given resistance to isoniazid is 0.86. The weights on the star tree
found in the first column of Table 2, range from 0.09 (SEAR) to
0.18 (FSU) and all standard errors are less than 0.026. With the
exception of the FSU, the probabilities associated with edges
beginning at the root in the non-star tree are all less than 0.10 (s.e.
v0.015), reflecting the relatively low prevalence of resistance
observed among treatment-naı ¨ve patients. In contrast, for the
FSU, the probability associated with the edge from the root is 0.27
(s.e.=0.007).
Results for treatment-experienced patients
A prespecified mixture model was fit to the data on treatment-
experienced patients with the non-star trees from the fit to data on
naı ¨ve patients as specified components (Figure 3). The number of
Table 1. Breakdown of data by region.
AFR AMR EMR FSU NFSU-EUR SEAR WPR
naı ¨ve n=13229 n=12286 n=2642 n=7546 n=21585 n=4781 n=23603
0.11 0.15 0.15 0.39 0.08 0.15 0.18
(0.11,0.12) (0.14,0.15) (0.14,0.16) (0.38,0.40) (0.08,0.09) (0.14,0.16) (0.17,0.18)
experienced n=2357 n=2861 n=511 n=5335 n=2461 n=1553 n=3541
0.21 0.29 0.47 0.71 0.2 0.43 0.44
(0.2,0.23) (0.27,0.31) (0.42,0.51) (0.7,0.72) (0.19,0.22) (0.40,0.45) (0.43,0.46)
The first row displays sample size, proportion of the population resistant to any drug and the corresponding confidence interval for treatment-naı ¨ve patients and the
second row displays this information for patients with a previous treatment history. AFR=African region, AMR=region of the Americas, EMR=Easter Mediterranean
region, FSU=Former Soviet Union region, NFSU-EUR=Non-Former Soviet Union European region, SEAR=South-East Asian region, WPR=Western Pacific region.
doi:10.1371/journal.pcbi.1002973.t001
Figure 3. Non-star tree structures from mixture models for treatment-naı ¨ve patients. (a) non-star tree for AFR and NFSU-EUR. (b) non-star
tree for AMR, EMR, FSU, SEAR and WPR. Nodes={WT=wild type, H=isoniazid, R=rifampin, E=ethambutol and S=streptomycin }.
doi:10.1371/journal.pcbi.1002973.g003
Mixture Models with Prespecified Elements
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model to the data from treatment-experienced patients. The trees
represented exclusively in the model for treatment-experienced
patients describe pathways for resistance that are unique to this
population (i.e. not observed among the treatment-naı ¨ve). Models
for each region, with the exception of SEAR, contain two
unspecified trees, one of which is the star tree, and the other of
which is shown in Figure 4. The model describing the SEAR
contains three unspecified trees: the star tree, and the trees shown
in Figure 4(a) and 4(c). Each of the three different non-star tree
structures, contain the edge H?R. The non-star tree for the EMR
and SEAR, is the only structure in which streptomycin, not
isoniazid, is the child node of the root. The analysis of resistance
patterns from treatment-naı ¨ve and experienced patients produces
Table 2. Posterior nodes and standard deviations of mixture model parameters describing resistance in treatment-naı ¨ve patients.
Region Mixture Model Parameters
AFR a1 WT?HW T ?RW T ?EW T ?S a2 WT?HH ?RR ?EH ?S
0.16(0.007) 0.32(0.022) 0.047(0.006) 0.04(0.005) 0.35(0.020) 0.84(0.007) 0.02(0.003) 0.86(0.094) 0.51(0.043) 0.70(0.039)
AMR a1 WT?HW T ?RW T ?EW T ?S a2 S?HH ?RR ?EW T ?S
0.11(0.006) 0.45(0.026) 0.19(0.015) 0.11(0.010) 0.20(0.025) 0.89(0.006) 0.32(0.021) 0.46(0.039) 0.46(0.049) 0.079(0.004)
EMR a1 WT?HW T ?RW T ?EW T ?S a2 S?HH ?RR ?EW T ?S
0.13(0.026) 0.27(0.052) 0.17(0.038) 0.09(0.023) 0.32(0.057) 0.87(0.026) 0.42(0.079) 0.42(0.077) 0.78(0.091) 0.08(0.014)
FSU a1 WT?HW T ?RW T ?EW T ?S a2 S?HH ?RR ?EW T ?S
0.18(0.007) 0.79(0.015) 0.29(0.016) 0.36(0.016) 0.38(0.022) 0.82(0.007) 0.64(0.013) 0.58(0.019) 0.62(0.023) 0.27(0.007)
NFSU-EUR a1 WT?HW T ?RW T ?EW T ?S a2 WT?HH ?RR ?EH ?S
0.13(0.005) 0.35(0.018) 0.047(0.006) 0.03(0.004) 0.26(0.014) 0.87(0.005) 0.01(0.001) 0.92(0.065) 0.58(0.048) 0.69(0.044)
SEAR a1 WT?HW T ?RW T ?EW T ?S a2 S?HH ?RR ?EW T ?S
0.09(0.008) 0.71(0.044) 0.17(0.023) 0.12(0.018) 0.28(0.046) 0.91(0.008) 0.25(0.048) 0.69(0.130) 0.68(0.090) 0.08(0.007)
WPR a1 WT?HW T ?RW T ?EW T ?S a2 S?HH ?RR ?EW T ?S
0.11(0.004) 0.67(0.016) 0.27(0.011) 0.16(0.009) 0.28(0.019) 0.89(0.004) 0.34(0.017) 0.38(0.025) 0.65(0.048) 0.10(0.003)
The four columns following ai represent the edges and corresponding edge weights associated with tree i. The edge weight is the conditional probability of being
resistant to the child node given resistance to the parent node has occurred. If the parent node is the root (WT), the edge weight is the marginal probability of
becoming resistant to the child node. Nodes={WT=wild type, H=isoniazid, R=rifampin, E=ethambutol and S=streptomycin }.
doi:10.1371/journal.pcbi.1002973.t002
Figure 4. Non-star tree structures from mixture models for treatment-experienced patients. (a) non-star tree for AFR, FSU, NFSU-EUR,
SEAR and WPR. (b) non-star tree for AMR (c) non-star tree for EMR and SEAR.
doi:10.1371/journal.pcbi.1002973.g004
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SEAR.
The results of analyses are shown in Table 3. Because there is
only one prespecified tree, the measures of similarity is the weight
for the unspecified tree shown in the first column of Table 3. In
our application, the measure of similarity is the probability that a
treatment-experienced patient follows a pathway identical to that
seen in treatment-naı ¨ve patients. It ranges from 0.29 to 0.71 and
all standard errors are less than 0.18. The breakdown for each
region is as follows: 0.52 (AFR, s.e.=0.18), 0.71 (AMR,
s.e.=0.03), 0.36 (EMR, s.e.=0.12), 0.33 (FSU, s.e.=0.03), 0.48
(NFSU-EUR, s.e.=0.18), 0.29 (SEAR, s.e.=0.12), and 0.51
(WPR, s.e.=0.06).
As shown in Izu et al., bootstrap methods provide information
regarding the stability of these tree structures. For each region, a
set of candidate tree structures are obtained for naı ¨ve and
treatment-experienced patient from fitting 30 bootstrap samples.
The program Mtreemix [6] was used to fit Beerenwinkel’s mixture
model to data from naı ¨ve patients and an adaption to the
Mtreemix program was used to fit our prespecified mixture model
to data from treatment-experienced patients. All candidate sets
contain fewer than four structures with the exception of the
NFSU-EUR and SEAR for treatment-experienced patients (five
and eight structures, respectively). Results of Izu et al. imply that
estimates from models where more structures occur in the set of
candidate trees are less stable. Results provided in Table 3 show
that the standard deviations of the posterior distribution for the
branching tree parameters in these regions are relatively high.
Simulation study
In analyses described above, we prespecified a single tree in our
mixture model. This section presents the results of simulations to
gauge the accuracy of our methods. Data are simulated from the
seven resulting mixture models from the treatment-experienced
data. In each of the models, labeled simulations 1–7, one tree
structure and its edge weights are prespecified and treated as
known. We estimate the structure and corresponding edge weights
for the remaining unspecified portion of the model as well as all
tree weights.
Table 4 shows how often the correct tree structure is chosen.
The agreement between these results and those from the bootstrap
analyses (Table 5) are generally high, with some notable
exceptions. The results from AFR, EMR, and WPR appear to
be stable in both analyses and the results for SEAR are particularly
unstable in both. In the AMR, FSU and NFSU-EUR, the results
from the simulation samples differ from the results from the
bootstrap samples. The NFSU-EUR shows the largest difference.
The correct tree structure is chosen in 84% of the simulations, but
in only 3% of the bootstrap samples. The tree structure chosen in
83% of the bootstrap samples is similar to the correct tree except
for the non-star tree in the unspecified portion of the model. The
set of edges for the non-star tree is: E={WT?H, H?R, H?E,
H?S}. We compared the distribution of the bootstrap samples
that resulted in this alternative tree and the simulation samples
resulting in the correct tree. Eight of the sixteen multinomial
parameters show different distributions in the bootstrap compared
to the simulation samples. We believe that these differences
constitute the main driver of this discrepancy. Such differences
could make it difficult for the data to distinguish between closely
related trees (e.g. those that differ by a single edge) that explain the
data equally well.
The results from fitting the models are shown in Table 6, which
provides the coverage for each parameter estimated in the seven
models. Coverage is defined as the percentage of time the 95%
credible intervals contain the true parameter, given the simulation
resulted in the correct tree structure. Of all seven simulations, all
parameter estimates have coverage higher than 90%. Our
simulations show that when the tree structure is correct, the
mixture model parameters are well estimated.
Discussion
This paper describes methods to estimate partially prespecified
mixture models which can be used to compare two populations.
Our model is applied to investigate patterns of resistance amongst
treatment naı ¨ve and experienced patients. Trees from treatment-
naı ¨ve data (Figure 3) reflect pathways from strains which have
demonstrated the ability to be transmitted and cause disease. Trees
from treatment-experienced patients (Figure 4) describe pathways
from a combination of transmitable and reproducible strains and
those which may have suffered some cost in terms of their ability to
transmit. There are different explanations for the patterns we
observe in the two populations and these methods cannot
definitively differentiate among them. Below, we review our results
and use them to generate hypotheses about underlying mechanisms
of TB resistance which may be worthy of further testing.
In the AFR, EMR, NFSU-EUR and SEAR the same tree
structure arises from both treatment-naı ¨ve and experienced
patients, implying the pathways to multi-drug resistance are
similar in both populations. One possible explanation is that in
these regions, all pathways result in transmissible resistant TB
strains. Factors that are region specific provide other possible
explanations. For example, there is a high prevalence of HIV in
the AFR. Patients with suppressed immune systems may be more
susceptible to strains that have lower overall reproductive fitness,
thereby permitting all pathways observed among re-treatment
cases to be also seen in naı ¨ve cases [7]. The NFSU-EUR has the
Table 4. The percentage of simulations in which the correct
tree structure is chosen.
Simulation Percentage
1 (AFR) 98.6
2 (AMR) 70.5
3 (EMR) 77.3
4 (FSU) 100
5 (NFSU-EUR) 84.2
6 (SEAR) 39.8
7 (WPR) 100
The region simulated is shown in parenthesis.
doi:10.1371/journal.pcbi.1002973.t004
Table 5. Number of different structures that arose from 30
bootstrap samples fit to naı ¨ve and treatment-experienced
patients in each region.
AFR AMR EMR FSU
NFSU-
EUR SEAR WPR
naı ¨ve 4 (53) 1(100) 2(77) 2(07) 2(57) 1(100) 1 (100)
experienced 3(87) 4(40) 3 (37) 1(100) 5(2) 8(20) 1(100)
The number inside the parenthesis is the percentage of structures which were
the same as that of the original sample.
doi:10.1371/journal.pcbi.1002973.t005
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For both naı ¨ve and experienced patients in this region, much
highly resistant disease is observed among immigrants from areas
where the prevalence of drug resistance is high [8]. One potential
explanation is that the majority of highly resistant disease in this
region results from transmission with only minimal contribution of
acquired resistance.
In contrast, analysis of AMR, FSU, SEAR and WPR resulted in
branching trees which differ among treatment-naı ¨ve and experi-
enced patients. This tends to imply that some pathways to
resistance produce strains that are relatively less transmissible and
cause disease in secondary hosts. Alternatively, it may be that new
resistance pathways appearing first among re-treatment cases
through acquisition may not have had enough time to be observed
among new cases.
Among treatment-naı ¨ve patients, the pathway of the most
common tree begins with streptomycin; however, in treatment-
experienced patients, the majority of the trees, it begins with
isoniazid. This difference may reflect the history of TB treatment.
Streptomycin was the first anti-TB drug in general use followed by
isoniazid and then rifampin. It is also possible that in some settings
(and with some resistance-conferring mutations), resistance to
isoniazid is associated with a reproductive fitness cost that
decreases the microbes transmissibility or ability to cause disease
[9–11]. It is unlikely that this ordering of mutations reflects current
sequencing of drug use since in most settings the vast majority of
cases will be treated simultaneously with four drugs (rifampin,
isoniazid, ethambutol and pyrazinamide) [12]. Only in rare
settings is streptomycin (the only antibiotic of the four reported
here that requires injection) used in first-line regimens for treating
tuberculosis.
Each non-star tree describing both treatment-naı ¨ve and
experienced patients contains the edge H?R. This important
edge defines the development of multidrug resistant TB (MDR-
TB). Given that a strain follows a pathway associated with the tree
under study, the weight corresponding to the edge H?R is the
conditional probability of the strain being MDR given that it is
resistant to isoniazid (INH). This edge weight in the trees for naı ¨ve
patients provides insight into the probability of MDR-TB given
INH resistance in strains that are being transmitted. Except for the
AFR, the H?R edge weight is lower in trees associated with
treatment-naı ¨ve patients, suggesting in these regions, the condi-
tional probability of MDR-TB given INH resistance may be lower
among transmitted strains.
The measure of similarity provides a quantitative measure of the
degree of similarity of two populations. We note that it does not
directly provide information regarding the process of acquiring
resistance in the two populations. Resistance pathways seen in the
sample of treatment- naı ¨ve patients may not actually represent
every possible pathway associated with this population. In
addition, patients presenting for re-treatment who were originally
infected with resistant strains may also have acquired additional
resistance [13]. Therefore, comparison of tree structures from
treatment-naı ¨ve and treatment-experienced patients cannot serve
as a basis for estimating the proportion of the latter who were
originally infected with resistance strains. Nonetheless, the
proportion of drug-resistant and MDR TB attributable to
transmission found in several molecular epidemiologic studies,
38% to 53%, and 64% respectively are similar to the weights
associated with trees observed in treatment-naı ¨ve patients [14–17].
The large amount of data from treatment-naı ¨ve patients allows
us to estimate reliably the prespecified portion of the model. In
some settings, it may not be appropriate to assume that branching
trees are known for a portion of the model. The Bayesian
approach permits incorporation of uncertainty by placing a prior
distribution on the parameters of the prespecified trees; the
methods of Szabo and Boucher [18] that permit incorporation of
measurement error into the mixture model can also be used. We
would have included this approach in our analysis had such
measures been available in the settings where the data were
collected. In other settings, it may be preferable to avoid
prespecification of model components and estimate all model
parameters completely from available data. To aid in such
endeavors, our model could be naturally extended to include other
covariates, such as indicator variables for different populations.
Izu et al. discuss the possibility that multiple structures may
describe data equally well as was possibly the case in the NFSU-
EUR. The authors recommend using bootstrap methods and
simulation to assess reliability of results. In such situations,
examining the similarities among the different plausible tree
structures provides insight regarding resistance pathways. In the
results described above, all of the trees resulting from the bootstrap
samples shared many of the same properties. The most notable
similarity was the role of E as the child node to R in 96.5% and
72.9% of the resulting structures from the bootstrap samples across
all regions for naı ¨ve and experienced patients, respectively. 92.7%
of the bootstrap samples across all regions for both groups of
patients resulted in a structure with H as an ancestor to R,
implying resistance to isoniazid precedes resistance to rifampin–a
finding that has also been previously described.
In summary, the proposed methods permit investigation of
pathways to resistance in treatment-naı ¨ve and treatment-experi-
enced patients, subject to limitations describe above. These results
are useful for formulating questions regarding the biology and
epidemiology of drug resistant tuberculosis and can help generate
testable hypotheses about which pathways to multiple drug
resistance may be most likely to generate fit strains capable of
being successfully transmitted. The analyses presented here are
limited by the fact that only phenotypic resistance data were
available. As discussed in Izu et al., genotypic data that permit
inference regarding the pathways by which specific drug-resistance
conferring mutations accumulate would allow for refinement of
hypotheses that can be tested. Although the focus of this paper is
on tuberculosis, our methods can be generalized to any biological
process for which the assumption of an ascending markov process
applies.
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